Cargando…
Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer
BACKGROUND: Tamoxifen is the standard endocrine therapy for breast cancers, which require metabolic activation by cytochrome P450 enzymes (CYP). However, the lower and variable concentrations of CYP activity at the tumor remain major bottlenecks for the efficient treatment, causing severe side-effec...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819296/ https://www.ncbi.nlm.nih.gov/pubmed/29463260 http://dx.doi.org/10.1186/s12951-018-0345-2 |